IL6 and non-small cell lung carcinoma: An analysis of 47 NSCLC patients showed that patients with a decreasing level of IL-6 after ICI treatment experienced better PFS than those with stable or increasing level of IL-6 (11 vs. 4 months, HR = 0.45; 95% CI = 0.23–0.89, p = 0.04) [145].